Shenzhen Salubris Pharmaceuticals Co., Ltd.
002294
Classifica tra le azioni
#3422
Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris... Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris Pharmaceuticals Co., Ltd. operates across the entire pharmaceutical value chain, from research and development to manufacturing and sales. The company primarily focuses on critical therapeutic areas within China, including cardiovascular, anti-diabetic, anti-cancer, and orthopedic medicine. Its diverse product portfolio features a variety of cardiovascular and cerebrovascular medications, such as allisartan isoproxil and clopidogrel bisulfate tablets, alongside injectable options like bivalirudin. A significant offering is the recombinant SeV-hFGF2/dF Injection, specifically developed for the treatment of diabetic foot disease. Salubris also manufactures anti-tumor and orthopedic drugs. Furthermore, its anti-infective range encompasses numerous injectable antibiotics, including ceftazidime and ceftriaxone sodium, as well as oral preparations such as azithromycin dispersible and levetiracetam tablets. The firm also innovates in biotechnological drugs, developing recombinant proteins and monoclonal antibodies. Complementing its domestic operations, Shenzhen Salubris Pharmaceuticals engages in the import, in-licensing, and out-licensing of medicines, particularly for European markets.
Prezzo delle azioni
$4.48
Capitalizzazione di mercato
$4.99B
Variazione (1 giorno)
-5.20%
Variazione (1 anno)
-41.89%
Paese
CN
Scambia Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
Categoria
Healthcare
Storico del prezzo dell'azione per Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294)
Prezzo di chiusura più alto: $4.49 il 2026-10-01
Prezzo di chiusura più basso: $1.19 il 2009-09-01
Prezzo di chiusura più basso: $1.19 il 2009-09-01
Storico del prezzo dell'azione di Shenzhen Salubris Pharmaceuticals Co., Ltd. dal 2009 al 2026
Andamento annuale del prezzo dell'azione
| Anno | Performance |
|---|---|
| 2026 (TTM) | -19.84% |
| 2025 | 80.15% |
| 2024 | -0.06% |
| 2023 | -1.96% |
| 2022 | 6.35% |
| 2021 | 1.19% |
| 2020 | 61.60% |
| 2019 | -18.68% |
| 2018 | -47.95% |
| 2017 | 49.36% |
| 2016 | -11.86% |
| 2015 | 30.44% |
| 2014 | 5.05% |
| 2013 | 45.58% |
| 2012 | 57.04% |
| 2011 | -36.22% |
| 2010 | 64.27% |
| 2009 | 0.00% |
Prezzo dell'azione per aziende simili o concorrenti
| Azienda | Prezzo dell'azione | Variazione 1a% | Il paese |
|---|---|---|---|
| $442.77 | -15.99% |
US
|
|
| $197.82 | -45.30% |
FR
|
|
| $170.48 | 12.48% |
JP
|
|
| $200.31 | 35.45% |
US
|
|
| $70.09 | -8.42% |
CH
|
